Quick answer: latest quarter results, by ticker or company name

Reported Q: Q2 2025 Rev YoY: +3.0% EPS YoY: +5.7% Move: -0.07%

Thermo Fisher Scientific

0R0H.L

$544.34 -0.07%

Exchange LSE Sector Healthcare Industry Medical Pharmaceuticals

Q2 2025

Published: Aug 1, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 0R0H.L

Reported

Report Date

Aug 1, 2025

Quarter Q2 2025

Revenue

10.86B

YoY: +3.0%

EPS

4.28

YoY: +5.7%

Market Move

-0.07%

Previous quarter: Q1 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $10.86B up 3% year-over-year
EPS of $4.28 increased by 5.7% from previous year
Gross margin of 37.3%
Net income of 1.62B
"" -

0R0H.L

Company 0R0H.L

Period Q2 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 10, 2026

Executive Summary

Thermo Fisher Science’s QQ2 2025 results reflect a company with resilient demand across its Life Sciences Solutions and Analytical Instruments franchises, delivering modest top-line growth and solid cash generation, even as gross margins faced headwinds from mix and input costs. Revenue rose to $10.855 billion, up 2.98% year over year and 4.74% quarter over quarter, underscoring continued underlying demand for life sciences tools and diagnostics. Despite gross profit pressure, operating income expanded, driving net income and EPS higher, supported by disciplined operating expenses and strong cash flow.

Key Performance Indicators

Revenue

Increasing

10.86B

QoQ: 4.74% | YoY: 2.98%

Gross Profit

Decreasing

4.05B

37.29% margin

QoQ: -4.64% | YoY: -6.81%

Operating Income

Increasing

1.92B

QoQ: 4.18% | YoY: 9.04%

Net Income

Increasing

1.62B

QoQ: 7.30% | YoY: 4.46%

EPS

Increasing

4.28

QoQ: 7.27% | YoY: 5.68%

Revenue Trend

Margin Analysis

Financial Highlights

- Revenue: $10.855B; YoY +2.98%; QoQ +4.74%
- Gross Profit: $4.048B; Gross Margin 37.29%; YoY -6.81%; QoQ -4.64%
- Operating Income: $1.917B; Operating Margin 17.66%; YoY +9.04%; QoQ +4.18%
- EBITDA: $2.798B; EBITDA Margin ~25.8%
- Net Income: $1.617B; Net Margin 14.90%; YoY +4.46%; QoQ +7.30%
- EPS: $4.28; YoY +5.68%; QoQ +7.27%
- Operating Cash Flow: $1.399B; Free Cash Flow: $1.105B; FCF per share $2.92
- Dividends paid: $162M; Share repurchases: none
- Balance Sheet: Cash & equivalents $4.576B; Total debt $35.229B; Net debt $30.653B; Total assets $101.23B; Total equity $50.511B; Goodwill $47.249B; Intangibles $15.148B
- Liquidity: Current ratio 1.933; Quick ratio 1.496; Cash ratio 0.360
- Leverage & Coverage: Debt/Capitalization 0.411; Debt/Equity 0.697; Interest coverage 4.75
- Efficiency: DSO 83.20 days; DIO 73.50 days; DPO 39.40 days; CCC ~117.30 days
- Valuation (various): P/E 23.86; P/S 14.22; EV/Revenue 66.11; Dividend yield 0.105%; P/BV 3.06

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	10.86B	2.98%	4.74%
Gross Profit	4.05B	-6.81%	-4.64%
Operating Income	1.92B	9.04%	4.18%
Net Income	1.62B	4.46%	7.30%
EPS	4.28	5.68%	7.27%

Key Financial Ratios

Gross Profit Margin

Fair

37.30%

Gross profit margin is moderate, room for improvement in cost management

Operating Profit Margin

Good

17.70%

Operating margin is healthy and competitive within industry standards

Net Profit Margin

Good

14.90%

Net profit margin is healthy and competitive within industry standards

Return on Assets

Weak

1.60%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

3.20%

Return on equity suggests inefficient capital allocation

Current Ratio

Healthy

1.93

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

Elevated

0.70

Debt-to-equity shows significant leverage, monitor debt levels

P/E Ratio

Fair Value

23.86x

P/E ratio in line with market averages

Price to Book

Premium

3.06x

Trading at premium to book value, reflects strong intangibles or growth

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q3 2025	11,122.00	4.27	+4.9%	View
Q2 2025	10,855.00	4.28	+3.0%	View
Q1 2025	10,364.00	3.98	+0.2%	View
Q4 2024	11,395.00	4.78	+10.2%	View
Q3 2024	10,598.00	4.24	-2.7%	View

0R0H.L

Thermo Fisher Scientific

Q3 2025 Report

Thermo Fisher Scientific Inc (0R0H.L) QQ3 2025 Results – Revenue Growth, Margin Strength, and Robust Cash Flow Amid Mixed Net Income Dynamics...

Read full report

0R0H.L

Thermo Fisher Scientific

Q1 2025 Report

Thermo Fisher Scientific Inc (0R0H.L) QQ1 2025 Results Analysis — Solid Margin Profile Amidst Seasonal Revenue Sequencing; Strong Cash Generation Su...

Read full report

0R0H.L

Thermo Fisher Scientific

Q4 2024 Report

Thermo Fisher Scientific Inc (0R0H.L) QQ4 2024 Results – Robust Margin Profile and Strong Cash Generation Amid Broad Market Leadership...

Read full report

0R0H.L

Thermo Fisher Scientific

Q3 2024 Report

Thermo Fisher Scientific Inc (0R0H.L) QQ3 2024 Results Analysis: Resilient profitability, margin discipline, and strategic activity in a high-growth L...

Read full report

Thermo Fisher Scientific (0R0H.L) Q2 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 0R0H.L Quarterly Reports

0R0H.L

0R0H.L

0R0H.L

0R0H.L

Q2 2025 Reports in Healthcare Sector

0Y0Y.L

0QYU.L

Related Financial Data

Sector Analysis: Healthcare

0R0H.L Full Profile

0R0H.L Financial Statements

Earnings Calendar